PMC3804541_01
(A) Fluorescein angiography of the left eye demonstrating two chorioretinal scars (white arrows) and a classic choroidal neovascular membrane (yellow arrows). (B) Spectral domain optical coherence tomography (Spectralis  HRA-OCT, Heidelberg Engineering, Inc., Carlsbad, CA, USA) point-to-point registration before and after the administration of the intravitreal injection of ranibizumab, demonstrating a thick, hyper-reflective, and taut posterior hyaloid, partially detached from the posterior pole exerting traction on the fovea. The steep V-shaped hyaloids curve and the thickened cystoid fovea are suggestive of vitreomacular traction (before), which demonstrate a resolution and reduction of macular thickness (after). (C) Spectral domain optical coherence tomography point-to-point registration at the next level, showing the release of the vitreous traction.
tcrm-9-391Fig1.jpg
PMC3804541_01_tcrm-9-391Fig1.jpg
f1-tcrm-9-391
Fundus fluorescein angiography showed the existence of a classic CNV, and optical coherence tomography (OCT) demonstrated a VMT with coexistent intraretinal fluid (Figure 1). Examination at that point revealed a BCVA of 20/100, and OCT showed a resolution of the vitreous traction with improvement of macular edema (Figure 1).
PMC3804541_02
(A) Indocyanine green angiography of the right eye (with magnified foveal area), demonstrating a classic choroidal neovascular membrane (white arrows) with retinal-choroidal anastomosis (yellow arrows). (B) Spectral domain optical coherence tomography (Spectralis  HRA-OCT, Heidelberg Engineering, Inc., Carlsbad, CA, USA) point-to-point registration, showing a taut, V-shaped, hyper-reflective posterior hyaloid attached on the fovea with coexistent macular edema, which resolved after administration of the intravitreal injection of ranibizumab.
tcrm-9-391Fig2.jpg
PMC3804541_02_tcrm-9-391Fig2.jpg
f2-tcrm-9-391
No signs of inflammation were present in either eye, and dilated fundus examination, fluorescein angiography, and OCT demonstrated the existence of macular edema with VMT with a background of a classic inflammatory neovascular membrane in the RE (Figure 2). Follow-up 1 week later, including OCT, revealed a BCVA of 20/50 in the RE with a vitreous traction resolution and reduced macular edema (Figure 2).